These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21940271)

  • 1. Treatment of chronic hepatitis C in a patient with Fanconi anaemia.
    Rogalska-Płońska M; Parfieniuk-Kowerda A; Lapiński TW; Flisiak R
    Adv Med Sci; 2011; 56(2):366-8. PubMed ID: 21940271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
    Younossi ZM; Nader FH; Bai C; Sjogren R; Ong JP; Collantes R; Sjogren M; Farmer D; Ramsey L; Terra K; Gujral H; Gurung C; Srishord M; Fang Y
    J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective granulocyte and monocyte apheresis as a new adjunct to enhance the efficacy of interferon-alpha + ribavirin in patients with high plasma hepatitis C virus.
    Sawada K; Kashiwamura S; Okamura H; Ohnishi K; Fukunaga K; Hirata I; Saniabadi A
    Dig Liver Dis; 2005 Jul; 37(7):515-21. PubMed ID: 15975539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C--a report from eastern India.
    Ray G; Pal S; Nayyar I; Dey S
    Trop Gastroenterol; 2007; 28(3):109-12. PubMed ID: 18383998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy in fanconi anaemia with bone marrow failure: a case report and review of the literature.
    Sorbi F; Mecacci F; Di Filippo A; Fambrini M
    BMC Pregnancy Childbirth; 2017 Feb; 17(1):53. PubMed ID: 28158987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
    Simón-Talero M; Buti M; Esteban R
    J Viral Hepat; 2012 Jan; 19 Suppl 1():14-7. PubMed ID: 22233409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
    Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
    Snoeck E; Wade JR; Duff F; Lamb M; Jorga K
    Br J Clin Pharmacol; 2006 Dec; 62(6):699-709. PubMed ID: 17118125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N; Habibi MS; Brown A
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
    Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.
    Craxi A; Koutsounas S; Ogurtsov P; Chemello L; Maticic M; Torras J; Diago M; Tartaglione MT; Witthoeft T; Yu X; Faruqi R; Chaudhri E; Pedicone LD; Zuckerman E
    J Viral Hepat; 2012 Feb; 19(2):e120-5. PubMed ID: 22239509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    Aziz H; Raza A; Waheed Y; Gill U; Gill ML
    Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
    Koirala J; Gandotra SD; Rao S; Sangwan G; Mushtaq A; Htwe TH; Adamski A; Blessman D; Khardori NM
    J Viral Hepat; 2007 Nov; 14(11):782-7. PubMed ID: 17927614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus.
    Lebray P; Nalpas B; Vallet-Pichard A; Broissand C; Sobesky R; Serpaggi J; Fontaine H; Pol S
    Antivir Ther; 2005; 10(6):769-76. PubMed ID: 16218177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
    Tsubota A; Akuta N; Suzuki F; Suzuki Y; Someya T; Kobayashi M; Arase Y; Saitoh S; Ikeda K; Kumada H
    Intervirology; 2002; 45(1):33-42. PubMed ID: 11937769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study.
    da Silva LC; Bassit L; Ono-Nita SK; Pinho JR; Nishiya A; Madruga CL; Carrilho FJ
    J Gastroenterol; 2002; 37(9):732-6. PubMed ID: 12375147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.